The U.S. Food and Drug Administration (FDA) has approved a new treatment for relapsed or refractory multiple myeloma, a type of blood cancer. This treatment, known as belantamab mafodotin-blmf (Blenrep), is administered in combination with bortezomib (Velcade) and dexamethasone (BVd). The approval is a significant milestone in the field of oncology, offering new hope to patients who have exhausted other treatment options.
The approval is based on the results of the phase 3 DREAMM-7 trial, which evaluated the effectiveness of BVd compared to daratumumab (Darzalex) plus bortezomib and dexamethasone (DVd). The study included patients who had received at least two prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMID). The findings showed that BVd reduced the risk of death by 51% compared to DVd, with a median progression-free survival of 31.3 months versus 10.4 months.
The safety and tolerability of BVd were generally consistent with the known safety profiles of the individual agents, according to the news release. However, the FDA's Oncologic Drugs Advisory Committee raised concerns about the high incidence of ocular toxicity and serious adverse effects associated with BVd. Despite these concerns, the FDA ultimately approved the treatment, recognizing the urgent need for new therapies in multiple myeloma.
The approval of Blenrep is a significant advancement in the treatment of relapsed/refractory multiple myeloma, offering a potential for improved outcomes and quality of life for patients. It is the only anti-BCMA agent that can be administered across healthcare settings, including community centers, where 70% of patients receive care. This accessibility is crucial in ensuring that patients have access to effective treatments, regardless of their location.
The development of Blenrep is a testament to the ongoing efforts in the field of oncology to find innovative solutions for difficult-to-treat cancers. As the disease becomes refractory to treatments, patients face a relentless cycle of remission and relapse. Therefore, there is an urgent need for more effective treatment options that can offer patients more quality time with their loved ones.
